Objectives: The aim of this study was to evaluate pristinamycin in the treatment of MSSA bone and joint infection (BJI).
Patients And Methods: A retrospective, single-centre cohort study (2001-11) investigated outcome in adults receiving pristinamycin for MSSA BJI and pristinamycin-related adverse events (AEs).
Results: One hundred and two MSSA BJIs were assessed in 98 patients [chronic infection, 33.